In vitro killing of multidrug/extensively drug-resistant <i>Pseudomonas aeruginosa</i> by fosfomycin alone or in combination with antipseudomonal antibiotics

Slade-Vitković, Mia; Bedenić, Branka; Bielen, Luka; Batarilo, Ivanka; Kibel, Sara; Maravić-Vlahoviček, Gordana

doi:10.1080/1120009x.2022.2108247

Cited by 3 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two of the isolates were kindly provided by G. M. Rossolini (Department of Microbiology and Virology, Careggi University Hospital, 50135 Florence, Italy). Antibiotic susceptibility was determined in previous studies carried out by Slade-Vitković et al [ 34 ], and the isolates were categorized as multidrug-resistant (MDR) and/or extensively drug-resistant (XDR) according to Magiorakos et al [ 35 ]. To define resistance, the fosfomycin MIC breakpoint value was set at >64 µg/mL [ 36 ].…”

Section: Methodsmentioning

confidence: 99%

In Vitro Antibiofilm Activity of Fosfomycin Alone and in Combination with Other Antibiotics against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa

Slade-Vitković,

Batarilo,

Bielen

et al. 2024

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

Background: Due to its rapid resistance development and ability to form biofilms, treatment of Pseudomonas aeruginosa infections is becoming more complicated by the day. Drug combinations may help reduce both resistance and biofilm formation. Methods: Using the microtiter plate assay, we investigated the in vitro inhibition of biofilm formation and the disruption of preformed biofilms in multidrug-resistant and extensively drug-resistant clinical isolates of P. aeruginosa in the presence of peak plasma levels of eight antipseudomonal antibiotics alone and in combination with fosfomycin: ceftazidime, piperacillin/tazobactam, cefepime, imipenem, gentamicin, amikacin, ciprofloxacin and colistin. Results: Combination therapy was significantly superior to monotherapy in its inhibition of biofilm formation. The highest inhibition rates were observed for combinations with colistin, cefepime and ceftazidime. Conclusion: Our results support fosfomycin combination therapy as an enhanced prophylactic option. Moreover, combinations with β-lactam antibiotics and colistin demonstrated a more potent inhibition effect on biofilm formation than protein synthesis inhibitors.

show abstract

Section: Methodsmentioning

confidence: 99%

In Vitro Antibiofilm Activity of Fosfomycin Alone and in Combination with Other Antibiotics against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa

Slade-Vitković,

Batarilo,

Bielen

et al. 2024

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

show abstract

Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections

Wangchinda,

Pogue,

Thamlikitkul

et al. 2024

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Background IV fosfomycin is used against MDR Gram-negative bacilli (GNB) but has dose-limiting side effects, especially in patients with impaired kidney function. Objectives To determine the optimal dosage of IV fosfomycin for patients with varying degrees of kidney function. Methods Adult patients receiving IV fosfomycin for treatment of GNB were eligible. Five serial blood samples were collected after at least three doses of fosfomycin; plasma was assayed by LC-MS/MS and modelled by population pharmacokinetic analysis. The PTA for AUC24/MIC of 98.9 for Escherichia coli and Klebsiella pneumoniae, and 40.8 for Pseudomonas aeruginosa were computed by Monte Carlo simulations. Cumulative fractions of response (CFR) were analysed for each pathogen using EUCAST MIC distributions. Results A total of 24 patients were included. Creatinine clearance (CLCR) and gender significantly influenced fosfomycin clearance. The kidney function-adjusted dosing regimens are proposed by using the lowest dose that can achieve ≥90% PTA for AUC24/MIC of 98.9 at an MIC of ≤32 mg/L (EUCAST v.13 susceptibility breakpoint for Enterobacterales). For patients with normal kidney function (CLCR 91–120 mL/min), a dosage of 15 g/day is suggested. This regimen achieved 97.1% CFR against E. coli, whereas CFR was 72.9% for K. pneumoniae and 76.7% for P. aeruginosa. Conclusions A fosfomycin dosage of 15 g/day with adjustment according to kidney function provided high PTA and CFR when treating E. coli. This dosage is lower than that used in current practice and may improve tolerability. Higher dosages may be needed for P. aeruginosa; however, safety data are limited.

show abstract

Clinical pharmacists’ involvement in carbapenem antibiotics management at Wenzhou Integrated Hospital

Xu,

Pan,

Zeng

2023

World J Clin Cases

View full text Add to dashboard Cite

Rehabilitation of lower limb amputation in developing countries is quite challenging. Though there are basic to highly advanced prostheses available in India, the set-up is still facing difficulties in developing countries. Prosthetic management is difficult due to lack of availability of prostheses and reduced affordability among low income populations. In this review we highlighted the lower limb amputation and prosthetic rehabilitation status in India. Currently, India is advancing well in the rehabilitation field, but further studies are required to provide more evidence and recommendation.

show abstract

In vitro killing of multidrug/extensively drug-resistant Pseudomonas aeruginosa by fosfomycin alone or in combination with antipseudomonal antibiotics

Cited by 3 publications

References 48 publications

In Vitro Antibiofilm Activity of Fosfomycin Alone and in Combination with Other Antibiotics against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa

In Vitro Antibiofilm Activity of Fosfomycin Alone and in Combination with Other Antibiotics against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa

Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections

Clinical pharmacists’ involvement in carbapenem antibiotics management at Wenzhou Integrated Hospital

Contact Info

Product

Resources

About